135.79 USD
+0.22 (+0.16%)
135.8 USD
+0.01 (+0.01%)
NBIX gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. NBIX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: NBIX is growing strongly while it also seems undervalued. This makes NBIX very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year NBIX was profitable.
In the past year NBIX had a positive cash flow from operations.
In the past 5 years NBIX has always been profitable.
NBIX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
NBIX has a Return On Assets of 10.03%. This is amongst the best in the industry. NBIX outperforms 93.77% of its industry peers.
The Return On Equity of NBIX (14.25%) is better than 94.34% of its industry peers.
NBIX has a Return On Invested Capital of 11.10%. This is amongst the best in the industry. NBIX outperforms 94.91% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for NBIX is significantly below the industry average of 18.28%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| ROIC | 11.1% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
1.3 Margins
NBIX's Profit Margin of 15.95% is amongst the best of the industry. NBIX outperforms 92.26% of its industry peers.
NBIX's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 20.64%, NBIX belongs to the best of the industry, outperforming 94.91% of the companies in the same industry.
NBIX's Operating Margin has declined in the last couple of years.
The Gross Margin of NBIX (98.37%) is better than 97.74% of its industry peers.
In the last couple of years the Gross Margin of NBIX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.64% | ||
| PM (TTM) | 15.95% | ||
| GM | 98.37% |
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
2. Health
2.1 Basic Checks
NBIX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, NBIX has more shares outstanding
Compared to 5 years ago, NBIX has more shares outstanding
There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 8.02 indicates that NBIX is not in any danger for bankruptcy at the moment.
NBIX's Altman-Z score of 8.02 is fine compared to the rest of the industry. NBIX outperforms 78.87% of its industry peers.
There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.02 |
ROIC/WACC1.27
WACC8.77%
2.3 Liquidity
NBIX has a Current Ratio of 3.38. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
NBIX has a Current ratio (3.38) which is in line with its industry peers.
NBIX has a Quick Ratio of 3.27. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of NBIX (3.27) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.38 | ||
| Quick Ratio | 3.27 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 12.06% over the past year.
The Earnings Per Share has been growing by 58.39% on average over the past years. This is a very strong growth
NBIX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.61%.
Measured over the past years, NBIX shows a very strong growth in Revenue. The Revenue has been growing by 24.48% on average per year.
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%
3.2 Future
Based on estimates for the next years, NBIX will show a very strong growth in Earnings Per Share. The EPS will grow by 32.54% on average per year.
The Revenue is expected to grow by 12.05% on average over the next years. This is quite good.
EPS Next Y55.94%
EPS Next 2Y47.98%
EPS Next 3Y37.96%
EPS Next 5Y32.54%
Revenue Next Year21.48%
Revenue Next 2Y19.96%
Revenue Next 3Y16.2%
Revenue Next 5Y12.05%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 32.49, which means the current valuation is very expensive for NBIX.
Compared to the rest of the industry, the Price/Earnings ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 92.83% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of NBIX to the average of the S&P500 Index (27.19), we can say NBIX is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 18.85, the valuation of NBIX can be described as rather expensive.
94.72% of the companies in the same industry are more expensive than NBIX, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 23.92. NBIX is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.49 | ||
| Fwd PE | 18.85 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NBIX is valued cheaply inside the industry as 93.96% of the companies are valued more expensively.
94.91% of the companies in the same industry are more expensive than NBIX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.83 | ||
| EV/EBITDA | 19.97 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of NBIX may justify a higher PE ratio.
A more expensive valuation may be justified as NBIX's earnings are expected to grow with 37.96% in the coming years.
PEG (NY)0.58
PEG (5Y)0.56
EPS Next 2Y47.98%
EPS Next 3Y37.96%
5. Dividend
5.1 Amount
No dividends for NBIX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
135.79
+0.22 (+0.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.58%
Inst Owner Change0.19%
Ins Owners1.01%
Ins Owner Change0.04%
Market Cap13.54B
Revenue(TTM)2.68B
Net Income(TTM)428.00M
Analysts84.57
Price Target181.85 (33.92%)
Short Float %4.03%
Short Ratio3.81
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.55%
Min EPS beat(2)7%
Max EPS beat(2)26.1%
EPS beat(4)2
Avg EPS beat(4)-22.42%
Min EPS beat(4)-85.62%
Max EPS beat(4)26.1%
EPS beat(8)3
Avg EPS beat(8)-23.05%
EPS beat(12)4
Avg EPS beat(12)-75.32%
EPS beat(16)4
Avg EPS beat(16)-76.53%
Revenue beat(2)2
Avg Revenue beat(2)3.84%
Min Revenue beat(2)3.28%
Max Revenue beat(2)4.39%
Revenue beat(4)2
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-2.16%
Max Revenue beat(4)4.39%
Revenue beat(8)4
Avg Revenue beat(8)1.12%
Revenue beat(12)6
Avg Revenue beat(12)0.97%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)2.32%
PT rev (3m)7.05%
EPS NQ rev (1m)0.62%
EPS NQ rev (3m)6.25%
EPS NY rev (1m)-0.17%
EPS NY rev (3m)13.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.56%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)2.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.49 | ||
| Fwd PE | 18.85 | ||
| P/S | 5.05 | ||
| P/FCF | 22.83 | ||
| P/OCF | 21.26 | ||
| P/B | 4.51 | ||
| P/tB | 4.56 | ||
| EV/EBITDA | 19.97 |
EPS(TTM)4.18
EY3.08%
EPS(NY)7.2
Fwd EY5.31%
FCF(TTM)5.95
FCFY4.38%
OCF(TTM)6.39
OCFY4.7%
SpS26.91
BVpS30.12
TBVpS29.77
PEG (NY)0.58
PEG (5Y)0.56
Graham Number53.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| ROCE | 15.26% | ||
| ROIC | 11.1% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 16.25% | ||
| OM | 20.64% | ||
| PM (TTM) | 15.95% | ||
| GM | 98.37% | ||
| FCFM | 22.11% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
ROICexc(3y)30.35%
ROICexc(5y)27.29%
ROICexgc(3y)31.58%
ROICexgc(5y)28.03%
ROCE(3y)15.68%
ROCE(5y)15.92%
ROICexgc growth 3Y35.59%
ROICexgc growth 5Y-0.37%
ROICexc growth 3Y34.3%
ROICexc growth 5Y-0.94%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
F-Score5
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 147.14% | ||
| Cap/Sales | 1.63% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 109.17% | ||
| Profit Quality | 138.57% | ||
| Current Ratio | 3.38 | ||
| Quick Ratio | 3.27 | ||
| Altman-Z | 8.02 |
F-Score5
WACC8.77%
ROIC/WACC1.27
Cap/Depr(3y)126.53%
Cap/Depr(5y)144.2%
Cap/Sales(3y)1.41%
Cap/Sales(5y)1.47%
Profit Quality(3y)172.36%
Profit Quality(5y)166.13%
High Growth Momentum
Growth
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
EPS Next Y55.94%
EPS Next 2Y47.98%
EPS Next 3Y37.96%
EPS Next 5Y32.54%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%
Revenue Next Year21.48%
Revenue Next 2Y19.96%
Revenue Next 3Y16.2%
Revenue Next 5Y12.05%
EBIT growth 1Y-5.9%
EBIT growth 3Y41.04%
EBIT growth 5Y20.8%
EBIT Next Year4.42%
EBIT Next 3Y19.54%
EBIT Next 5Y18.39%
FCF growth 1Y54.17%
FCF growth 3Y33.71%
FCF growth 5Y32.31%
OCF growth 1Y55.54%
OCF growth 3Y32.41%
OCF growth 5Y31.38%
NEUROCRINE BIOSCIENCES INC / NBIX FAQ
What is the fundamental rating for NBIX stock?
ChartMill assigns a fundamental rating of 7 / 10 to NBIX.
What is the valuation status for NBIX stock?
ChartMill assigns a valuation rating of 8 / 10 to NEUROCRINE BIOSCIENCES INC (NBIX). This can be considered as Undervalued.
What is the profitability of NBIX stock?
NEUROCRINE BIOSCIENCES INC (NBIX) has a profitability rating of 8 / 10.
Can you provide the PE and PB ratios for NBIX stock?
The Price/Earnings (PE) ratio for NEUROCRINE BIOSCIENCES INC (NBIX) is 32.49 and the Price/Book (PB) ratio is 4.51.